---
title: "Endra Life Sciences | 8-K: FY2025 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281240294.md"
datetime: "2026-03-31T20:35:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281240294.md)
  - [en](https://longbridge.com/en/news/281240294.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281240294.md)
---

# Endra Life Sciences | 8-K: FY2025 Revenue: USD 0

Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -8.93, missing the estimate of USD -6.59.

EBIT: As of FY2025, the actual value is USD -5.763 M.

### Fourth Quarter 2025 Financial Results

-   **Cash Flow from Operations**: Cash used in operations increased to $1.6 million in the fourth quarter of 2025, compared with $1.5 million in the fourth quarter of 2024.
-   **Operating Expenses**: Operating expenses decreased to $1.6 million in the fourth quarter of 2025, compared with $4.3 million in the same period last year.
-   **Net Loss**: The net loss for the fourth quarter of 2025 was - $3.2 million, compared with a net loss of - $4.2 million in the fourth quarter of 2024.

### Full Year 2025 Financial Results

-   **Operating Expenses**: Operating expenses in 2025 decreased to $5.8 million, compared with $10.8 million in 2024, which included a - $2.3 million non-cash inventory valuation charge.
    -   Research and development expenses were $1,849,996 in 2025, down from $3,190,293 in 2024.
    -   Sales and marketing expenses were $189,470 in 2025, down from $571,040 in 2024.
    -   General and administrative expenses were $3,723,635 in 2025, down from $7,055,814 in 2024.
-   **Operating Loss**: The operating loss was - $5,763,101 in 2025, significantly reduced from - $10,817,147 in 2024.
-   **Net Loss**: The company reported a net loss of - $7.0 million in 2025, an improvement from a net loss of - $11.5 million in 2024, primarily driven by lower operating expenses.

### Balance Sheet Highlights (as of December 31, 2025)

-   **Cash and Cash Equivalents**: ENDRA Life Sciences Inc. had approximately $762,000 in cash and cash equivalents.
-   **Digital Assets**: The company held approximately $2.0 million in its Digital Asset Treasury.
-   **Total Assets**: Total assets were $3,853,797 as of December 31, 2025, down from $4,452,362 as of December 31, 2024.
-   **Total Liabilities**: Total liabilities were $1,593,677 as of December 31, 2025, down from $1,891,996 as of December 31, 2024.
-   **Total Stockholders’ Equity**: Total stockholders’ equity was $2,260,120 as of December 31, 2025, down from $2,560,366 as of December 31, 2024.
-   **Accumulated Deficit**: The accumulated deficit was - $110,465,509 as of December 31, 2025, compared to - $103,438,099 as of December 31, 2024.

### Other Financial Items

-   **Change in Fair Value of Digital Assets**: The change in fair value of digital assets resulted in a - $995,161 impact in 2025.
-   **Warrant Expense**: Warrant expense was - $665,030 in 2025, a decrease from - $7,323,685 in 2024.
-   **Changes in Fair Value of Warrant Liability**: This resulted in a gain of $319,537 in 2025, compared to a gain of $3,447,737 in 2024.

### Business Outlook

ENDRA Life Sciences Inc.’s Board of Directors initiated a process on March 25, 2026, to evaluate strategic alternatives aimed at maximizing shareholder value. The company plans to continue executing its strategic and operating initiatives throughout this review process. A timetable for the completion of this evaluation has not been set.

### Related Stocks

- [NDRA.US](https://longbridge.com/en/quote/NDRA.US.md)

## Related News & Research

- [How Beaten-Down Tempus AI Stock Offers a Lottery Ticket for Traders Here](https://longbridge.com/en/news/286786866.md)
- [Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR](https://longbridge.com/en/news/286897088.md)
- [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)
- [Insider Sales And New Institutional Stake Reframe Entegris Valuation Debate](https://longbridge.com/en/news/286662658.md)
- [Bank of America Discloses 2.98% Stake in Qiagen via AFM Filing](https://longbridge.com/en/news/286822362.md)